The American Journal of Pathology

INSTRUCTIONS TO AUTHORS

The American Journal of Pathology (AJP) publishes original papers on the cellular and molecular biology of disease. The Editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, and mechanisms and management of diseases of clinical interest. The specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and pathological means to communicate results. The impact and utility of the technical or intellectual content of the manuscript will be considered in the peer-review process.

Manuscript Categories. Regular Articles are categorized in the Table of Contents according to the following research topics: Biomarkers, Genomics, Proteomics, and Gene Regulation; Biophysical Imaging and Computational Biology; Cardiovascular, Pulmonary and Renal Pathology; Cell Injury, Repair, Aging and Apoptosis; Epithelial and Mesenchymal Cell Biology; Gastrointestinal, Hepatobiliary and Pancreatic Pathology; Growth Factors, Cytokines, Cell Cycle, Molecules; Immunopathology and Infectious Diseases; Matrix Pathobiology; Metabolic; Endocrine and Genitourinary Pathobiology; Molecular Pathogenesis of Genetic and Inherited Diseases; Musculoskeletal Pathology; Neurobiology, Stem Cells, Tissue Engineering and Hematopoietic Elements; Tumorigenesis and Neoplastic Progression; and Vascular Biology, Atherosclerosis and Endothelium Biology. Not all topic areas will appear in each issue, as this is dependent on the content of original research accepted for publication. Upon acceptance, authors will be asked for their preference of topic category assignment; however, the Editors will make the final determination regarding topic category placement.

Short Communications are intended to provide a forum for the rapid publication of timely and significant findings. In brief, Manuscripts in this category should be concise but definitive, may be more descriptive and less mechanistic than Regular Articles, and must not exceed 12 double-spaced typed pages (excluding references and legends) and a maximum of 3 to 4 figures and tables. Categorization of manuscripts in this category is at the Editor’s discretion.

In addition to original research articles, the Journal publishes articles categorized as Reviews, Mini-Reviews, Biological Perspectives, and Commentaries. Authors who wish to publish a Review or Mini-Review should send their manuscript vitae along with an outline of the proposed article for prior approval by the Editor-in-Chief. Reviews have a maximum of 5,000 references, and 4 tables or figures (one of which is mechanistic). Mini-Reviews have a maximum of 4,000 words, 50 references, and 2 tables or figures (one of which is mechanistic). Biological Perspectives and Commentaries are submitted by invitation only and relate to a concurrently published manuscript. All invited papers are subject to the same review process as unsolicited articles.

Review Process. The Editors perform an initial evaluation on all submissions to determine whether they believe the manuscript will achieve a sufficient priority score to warrant consideration for publication. The priority score is a function of the importance of the question addressed, the quality of the work, and the originality of the findings. Certain topics are designated as priority areas, i.e., major gaps in our knowledge of a disease or condition. Manuscripts in these areas will be given more rapid peer review. Manuscripts that do not address topics of high priority will be reviewed according to standard criteria described below.

Long manuscripts, in the case of Regular Articles, will be subjected to peer review for both content and format. The length and complexity of the manuscript will determine the number of reviewers. The first round of review will generally include two external reviews. The Associate Editor will review these two reviews, along with the corresponding author’s response, and then the manuscript will be sent out for secondary review (typically, two external reviews are sought). Authors are encouraged to identify up to five potential reviewers. Authors may also request specific reviewers not to be used due to prior personal or professional contact. Authors may also request that reviewers that are not well-versed in the field of research. The Editors will make every effort to respect requests that are well-founded, however, the Editors do have the authority to utilize such a reviewer if it is necessary for expert peer review. It is the practice of the Journal to conduct a blinded peer-review process. The peer-review process is kept completely confidential; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript. The reviewer comments and Associate Editor’s recommendation are evaluated by the Editor-in-Chief for disposition and transmittal to the authors. Every effort is made to complete the review process within 35 days of the date received.

Review Decisions. Only a portion of manuscripts will be accepted for publication. A number of worthy manuscripts will be rejected based on priority. The Journal will advise authors whether the manuscript is acceptable, with revisions, rejected but encourage resubmission (after major revision), or rejected. A manuscript may be returned to the authors without outside review if the Editors find it inappropriate for publication in this Journal. Appeals (rebuttals) to editorial decisions must be submitted within 60 days to be considered.

Journal Scientific Integrity Policy. The Journal has developed principles for defining scientific misconduct as well as procedures for handling such matters. General guidelines are described below; detailed information can be viewed at http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity. To report suspected misconduct relating to authors, reviewers, or Editors, send written complaint to the Editor-in-Chief, The American Journal of Pathology, 9550 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or ajp@asip.org. Issues relating to staff conduct should be directed to the ASP Executive Officer at American Society for Investigative Pathology, 9550 Rockville Pike, Bethesda, Maryland, USA 20814-3993 or mesobel@asip.org.

Author Conduct. Authorship is defined as 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the manuscript or revising it critically for important intellectual content; 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. When submitting a manuscript to the Journal, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. Authors should affix to submitted manuscripts a statement that all authors attest to the accuracy and completeness of the data and the conclusions drawn. The Editors will make every effort to respect requests that are well-founded; however, the Editors do have the authority to utilize such a reviewer if it is necessary for expert peer review. It is the practice of the Journal to conduct a blinded peer-review process. The peer-review process is kept completely confidential; it is considered a violation of this confidentiality for authors to identify or attempt to communicate directly with peer reviewers or Associate Editors regarding their manuscript.

The Editors will make the final determination regarding topic category placement. Authors may also request specific reviewers not to be used due to prior personal or professional contact. Authors may also request that reviewers not feel comfortable with the content of their research may retracted, reporting of conduct to the authors’ governing institutions, and/or the denial to consider any future submissions to the Journal. Misconduct does not include incidents of honest misjudgment or inadvertent error. Detailed information regarding possible misconduct can be found in the Journal Scientific Integrity Policy at http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity.

Manuscript Submission. Manuscripts should be submitted online via the Rapid Review system (http://www.rapidreview.com/ASIP2/CALogon.jsp). Authors are encouraged to submit manuscripts online, with instructions on preparing and submitting files can be found on the author submission website at the above URL. Authors having difficulty submitting files online should contact the online submission assistant at 1-866-326-7953. Manuscripts arising from research in developing countries may be eligible for waiver of the submission charge. Manuscripts will be reviewed in the order received. The Editors have the authority to suggest the reorganization of the Journal manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors.

The Editors will make the final determination regarding topic category placement. Authors may also request specific reviewers not to be used due to prior personal or professional contact. Authors may also request that reviewers not feel comfortable with the content of their research may retracted, reporting of conduct to the authors’ governing institutions, and/or the denial to consider any future submissions to the Journal. Misconduct does not include incidents of honest misjudgment or inadvertent error. Detailed information regarding possible misconduct can be found in the Journal Scientific Integrity Policy at http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity.

A non-refundable manuscript processing fee of US$50 is required with submission. This fee should be paid electronically at the time of submission. Manuscripts arising from research in developing countries may be eligible for waiver of the submission charge. Manuscripts will be reviewed in the order received. The Editors have the authority to suggest the reorganization of the Journal manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Manuscripts that meet the priority criteria and do not meet the research and scientific standards expected by the Editors will be returned to the authors. Manuscripts that do not meet the research and scientific standards expected by the Editors will be returned to the authors.

Authorship is defined as 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the manuscript or revising it critically for important intellectual content; 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3. When submitting a manuscript to the Journal, the corresponding author takes responsibility on behalf of all authors for the authorship, authenticity, and integrity of the research being reported. Authors should affix to submitted manuscripts a statement that all authors attest to the accuracy and completeness of the data and the conclusions drawn.

Manuscript Submission. Manuscripts should be submitted online via the Rapid Review system (http://www.rapidreview.com/ASIP2/CALogon.jsp). Authors are encouraged to submit manuscripts online, with instructions on preparing and submitting files can be found on the author submission website at the above URL. Authors having difficulty submitting files online should contact the online submission assistant at 1-866-326-7953. Manuscripts arising from research in developing countries may be eligible for waiver of the submission charge. Manuscripts will be reviewed in the order received. The Editors have the authority to suggest the reorganization of the Journal manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Manuscripts that meet the priority criteria and do not meet the research and scientific standards expected by the Editors will be returned to the authors. Manuscripts that do not meet the research and scientific standards expected by the Editors will be returned to the authors.

A non-refundable manuscript processing fee of US$50 is required with submission. This fee should be paid electronically at the time of submission. Manuscripts arising from research in developing countries may be eligible for waiver of the submission charge. Manuscripts will be reviewed in the order received. The Editors have the authority to suggest the reorganization of the Journal manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Manuscripts that meet the priority criteria and do not meet the research and scientific standards expected by the Editors will be returned to the authors. Manuscripts that do not meet the research and scientific standards expected by the Editors will be returned to the authors.

Manuscript Preparation. Manuscripts should be prepared in the style of the Journal and in accordance with The Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see http://www.icmje.org). The preferred file format is Microsoft Word. Spell check and proofread carefully. The corresponding author must state any conflicts of interest (both financial and personal), affirm that the manuscript has not been published previously and is not being considered concurrently by another publication, and affirm that all authors and acknowledged contributors have read and approved the manuscript. Submissions will be ineligible for review if previously published in any form (print or online) other than as an abstract. This includes any public posting of raw manuscripts or pre-reviews.

A non-refundable manuscript processing fee of US$50 is required with submission. This fee should be paid electronically at the time of submission. Manuscripts arising from research in developing countries may be eligible for waiver of the submission charge. Manuscripts will be reviewed in the order received. The Editors have the authority to suggest the reorganization of the Journal manuscripts not prepared in accordance with the submission guidelines detailed below may be returned to the authors. Manuscripts that meet the priority criteria and do not meet the research and scientific standards expected by the Editors will be returned to the authors. Manuscripts that do not meet the research and scientific standards expected by the Editors will be returned to the authors.
original data, which the authors must make available. Information can be found in the Journal Scientific Integrity Policy at http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity.

Digital Art: Digital figure files are required for submission. The American Journal of Pathology’s requirement for color images is RGB (Red, Green, Blue) color coordinates. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited in public databases (eg, GenBank). Each accession number should be listed with the figure legend. When DNA or protein sequences from the accession numbers included in the manuscript. When providing supplier information for materials sources, company name and location (city and state, or city and country) should be provided. Watermarking or other watermarks to acknowledge dual publication are not permitted. All novel materials and the procedures to prepare them should be described in sufficient detail to allow their reproduction (eg, DNA constructs, analytical procedures) and materials that are acquired investigational-use only status be clearly indicated. Publication in the Journal implies that the authors agree, upon receipt of the published article, to allow replication or reutilization of the methods and/or the data presented in the article, including whatever would be necessary for a skilled investigator to verify or replicate the claims. Authors must disclose upon submission any restrictions on the availability of materials or information, such as for patented or dual-purpose materials.

Reporting guidelines for specific study designs (eg, randomized controlled trials) can be found in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (Uniform Requirements for Manuscripts Submitted to Biomedical Journals. The sequence of figures should be presented in the manuscript at the discretion of the editors. Authors should be prepared to provide study protocol number(s) if requested. Authors should obtain permission from all individuals named (by full name) in the Acknowledgments who contributed substantially to the work reported (eg, data collection, data analysis, preparation of the manuscript). Any material that is acquired investigational-use only status should be clearly indicated. Publication in the Journal implies that the authors agree, upon receipt of the published article, to allow replication or reutilization of the methods and/or the data presented in the article, including whatever would be necessary for a skilled investigator to verify or replicate the claims. Authors must disclose upon submission any restrictions on the availability of materials or information, such as for patented or dual-purpose materials.

References. References should begin on a new page, be double-spaced and numbered in order of citation in the text, including citations in tables and figure legends. Use the format of “et al.,” with @ omitted (eg, “et al.” is acceptable). When the author of the reference is the first author, the initials of all authors should be cited at the beginning of the reference. If there is no author, cite the article as "Anonymous", with only the title of the item. Citations should conform to the style of the Journal. Examples follow:


in press: To be used only for papers accepted for publication. Cite as in the Journal with the title of the issue and volume number. Cite as in the Journal with the title of the issue and volume number. All symbols and abbreviations in the Table should be defined in the footnotes.

Tables. Tables should be typed double-spaced and submitted after the main text on separate pages, as part of the manuscript. The preferred file format for Tables is Microsoft Word; figure file formats (including those embedded in the text) are accepted. Authors are encouraged to carefully consider whether bar or line graphs should be submitted in grayscale or color, paying special attention to the clarity of the data. Legends should be submitted as separate figures or other non-typeset images. Color or gray shading is not permitted. Authors may use one of the following sequential symbols: *, †, ‡, §, ¶, ‖, ‖‖; these may be doubled up if needed. All symbols and abbreviations in the Table should be defined in the footnotes.

Figures. Figures should be submitted in grayscale or color, paying special attention to the clarity of the data. Legends should be submitted as separate figures or other non-typeset images. Color or gray shading is not permitted. Authors may use one of the following sequential symbols: *, †, ‡, §, ¶, ‖, ‖‖; these may be doubled up if needed. All symbols and abbreviations in the Table should be defined in the footnotes.

Preparation of Images (Ethics): Taking photographs of the same source under varied fields of view, light intensity, magnifications, or contrast conditions without disclosing that the data are not unique to the present study constitutes suspect scientific practice. Figures must be high contrast, well defined, and of top quality. Figures should be submitted in grayscale or color, paying special attention to the ability of the reader to distinguish between different data points. Figures may consist of multiple related panels (labeled A, B, C, etc) described under one figure legend. Each figure (with all of its related panels) should be arranged on a separate page as it should appear in final publication. Figure labels should appear in the upper left corner as uppercase letters; refrain from using sub-labels (Aa, Ab, Ai, A1, A2, etc) on multiple panels or in the same figure. The inclusion of color in line graphs, and any other notations. Descriptive text, rather than graphics inserted into the text, should be used when possible (eg, closed circles, open boxes, hatched bars, etc); alternatively, a legend key should be included in the figure. Statistically significant difference should be indicated by symbols (eg, * P < 0.05, ** P < 0.01, *** P < 0.001), defined by asterisks (*) or by other sequential symbols: †, ‡, §, ¶, ‖, ‖‖; these may be doubled up if needed. Values should be labeled by symbol in the image, with definitions appearing only in the legend. All abbreviations should also be defined in the footnotes.

Data Supplements and Non-Traditional Media. Figures and tables that are critical to the evaluation and understanding of the research presented, but which cannot be accommodated via the print medium (eg, video), will be considered for inclusion as electronic supplementary material (ESM). Authors should provide justification for inclusion of ESM figures and tables in the manuscript. ESM figures and tables should be double-spaced and submitted as part of the manuscript. All ESM material is not acceptable. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited in public databases (eg, GenBank). Each accession number should be listed with the figure legend. Figure legends should be submitted as part of the manuscript (separate from the figure files) and should describe any staining methods and detailed information regarding the staining procedures. There is no limit to the number of ESM figures or tables that can be submitted. ESM figures should be prepared in grayscale or color, paying special attention to the clarity of the data. Legends should be submitted as separate figures or other non-typeset images. Color or gray shading is not permitted. Authors should use the following sequential symbols: *, †, ‡, §, ¶, ‖, ‖‖; these may be doubled up if needed. Values should be labeled by symbol in the image, with definitions appearing only in the legend. All abbreviations should also be defined in the footnotes.

Data Supplements and Non-Traditional Media. Figures and tables that are critical to the evaluation and understanding of the research presented, but which cannot be accommodated via the print medium (eg, video), will be considered for inclusion as electronic supplementary material (ESM). Authors should provide justification for inclusion of ESM figures and tables in the manuscript. ESM figures and tables should be double-spaced and submitted as part of the manuscript. All ESM material is not acceptable. The sequences of oligonucleotides, if not previously published, should be provided. Novel DNA or protein sequences should be deposited in public databases (eg, GenBank). Each accession number should be listed with the figure legend. Figure legends should be submitted as part of the manuscript (separate from the figure files) and should describe any staining methods and detailed information regarding the staining procedures. There is no limit to the number of ESM figures or tables that can be submitted. ESM figures should be prepared in grayscale or color, paying special attention to the clarity of the data. Legends should be submitted as separate figures or other non-typeset images. Color or gray shading is not permitted. Authors should use the following sequential symbols: *, †, ‡, §, ¶, ‖, ‖‖; these may be doubled up if needed. Values should be labeled by symbol in the image, with definitions appearing only in the legend. All abbreviations should also be defined in the footnotes.

Publishing in The American Journal of Pathology automatically places authors in compliance with NIH Public Access Policy (see http://publicaccess.nih.gov/submit_process.htm, Submission Method A). Any article noted as being funded by NIH must include a link to the Digital Object Identifier (DOI) of the published article, in perpetuity. Failure to maintain a live, unrestricted link may result in retraction of the article by the Editors. That has been published previously (print or online) is not acceptable for posting as supplementary data. Instead, the appropriate reference(s) to the original publication should be made in the text and references. The Editors will make the final determination as to whether a given data set is essential to the manuscript and whether they will require publication of the material on the Journal website. Failure to relinquish required materials for online publication can result in the reversal of a manuscript’s acceptance.

Contact healthpermissions@elsevier.com regarding permission to deposit manuscripts in other government-sponsored repositories in cases where The American Journal of Pathology does not have a system in place to automatically deposit manuscripts on behalf of the authors. Digital preprints (ie, preprint server access) cannot be made available to the public twelve months after final print publication (unless the funding agency stipulates a sooner release date). Authors should therefore NOT complete a separate deposit of their material but will be contacted by PubMed Central for grant verification once the article has been received by the PMC article system. For information on how to cite articles in NIH grant applications, please visit http://www.nih.gov/pubs/AuthorNotice.cfm.

Financial Disclosure and Conflicts of Interest. All authors must disclose any current or former relationships (eg, employment, consultancies, board membership, stock ownership, funding, honoraria, expert testimony, patents or royalties, or other financial or industry-supplies that might be perceived as conflicts of interest). When disclosing financial interests, authors must describe all financial interests, whether or not they are currently active. This information should be provided at the time of submission and reiterated as part of copyright assignment. Failure to do so may result in manuscript rejection or editorial retraction of the article. Further information can be...
found in the Journal Scientific Integrity Policy at http://www.journals.elsevierhealth.com/periodicals/ajpa/content/integrity. Upon manuscript acceptance, all coauthors will be instructed to formally disclose all potential conflicts.

**Publication Charges**

**Figure and Table Charges:** Authors will be charged $550 per color figure, $50 per black & white or grayscale figure, and $50 per composed table, per printed page (ie, figures or tables necessitating more than one printed page will incur an additional charge). Corresponding authors of published manuscripts who are current, dues-paying regular members of ASIP at the time of submission will receive one free color figure as a benefit of membership; page charges will not be waived for ASIP members.

**Page Charges:** Authors will be charged $95 per printed page. Manuscripts arising from research in developing countries may be eligible for waiver of publication charges only if all authors are located in a qualifying country (for a list of eligible countries, see Group A and Group B countries at http://www.who.int/hinari/eligibility/en). Otherwise, page charges will not be waived, except for solicited editorials.

**Approval of Fees and Invoicing:** A summary of publication charges (figures, tables, and supplemental data) will be presented to the corresponding author of accepted manuscripts for approval prior to publication; final page charges cannot be determined until final publication. Color figure charges will not be waived, but color figures may be published in black and white, pending editorial approval. Requests for black and white figure publication must be made prior to execution of the publication charge approval form to avoid color charges. A final invoice will be presented immediately after publication; full payment is expected at that time. Failure to pay publication charges may result in the authors' inability to publish future articles in The American Journal of Pathology.

**Open Choice.** In addition to publication charges outlined above, authors may elect to participate in the Journal’s Open Choice program. Articles published under Open Choice will become immediately accessible on the Journal website upon publication, without the twelve-month subscriber-only access delay. Authors wishing to participate should contact the Editorial Office following manuscript acceptance. All copyright restrictions regarding reuse still apply. Cost to participate is $1500, which must be received before article restriction is lifted.

**Reprints.** Reprints should be ordered when page proofs are returned; an order form is included with the proofs. Late reprint orders may result in additional fees. Author reprints will be supplied in CMYK color mode because it is a printed medium, but electronic reprints will be supplied in RGB color mode for visualization on screen. There is no extra charge for color reprints. Each coauthor will receive one complimentary electronic (secure PDF) reprint. Additional electronic reprints can be ordered at the time page proofs are returned or at a later date. No hardcopy complimentary reprints are provided by the publisher.

**Proofs.** The corresponding author will be contacted by email once proofs are ready, and will be directed to download electronic proofs from a secure website. Electronic page proofs will be provided in RGB, thus reflecting the online quality. Image files will be converted to CMYK for the printed journal; all images published online will be in RGB. Full instructions on completing proof corrections will be provided with the downloaded proof. The author should check the proofs carefully, mark any printer’s errors, and answer queries as requested. Author changes should be kept to a minimum. Proof corrections and replacement figures (if any) must be returned within 48 hours to avoid any delay in publication.

**Cover Figure.** The cover figure is selected by the Editors from illustrations appearing in the current issue. Authors are encouraged to suggest a figure for consideration or include an additional cover figure submission along with their manuscript submission. Cover figures are published at no charge; cover reprints are available as cover stock reprints or posters (no complimentary cover reprints are provided by the publisher).

**Editorial Communications.** All correspondence concerning editorial matters should be addressed to the Editor-in-Chief at The American Journal of Pathology, 9650 Rockville Pike, Bethesda, Maryland, USA 20814-3993, faxed to 301-634-7961, or emailed to ajp@asip.org. **Appeals** (rebuttals) to editorial decisions must be submitted within 60 days to be considered. Letters to the Editor will be printed at the Editors’ discretion in the Correspondence section.

**Corrections** are published upon request and after editorial review. **Retractions** are published upon request of authors or their institutions and may also be published by the Journal following a determination of scientific misconduct. **Notes of Concern** are published in response to editorial concerns relating to scientific or publishing misconduct by authors or reviewers or to alert the scientific community of an ongoing investigation.

[Revised: January 2012]